Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study
Stephen J. Noga, Ralph V. Boccia(Center for Cancer and Blood Disorders), Ruemu Birhiray(The US Oncology Network), Bingxia Wang(Takeda (United States)), Robert Schlossman(University of Leeds), Sudhir Manda(Dartmouth–Hitchcock Medical Center), Roger M. Lyons(Hematology Oncology Associates), Presley Whidden(Millennium Engineering and Integration (United States)), Robert M. Rifkin(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo)
Cited by 4
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
|Blood|2010|866
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761